HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, reported a third-quarter net loss of $3 million, or $0.05 per share, for the period ended Sept. 30, 2026, compared with a net loss of $5.3 million, or $0.15 per share, in the prior-year period, according to the company's latest financial and operational results. The improvement matters to investors because it shows the company reducing its cost base while it funds a regulatory program aimed at one of the most time-sensitive conditions in medicine: heart attacks.
Operating expenses declined to $3.5 million from $5.3 million, and cash and cash equivalents totaled $6.1 million as of Sept. 30, 2026. HeartBeam also raised approximately $4 million in net proceeds during the fourth quarter through the date of the announcement, bringing pro forma cash to approximately $10.1 million. The company now expects a full-year 2026 net operating cash outflow of $12 million to $12.5 million, a figure that gives readers a concrete measure of how long its current resources may last as it prepares a pivotal trial. Details of the results are available in the full press release at https://ibn.fm/8CLXO.
Operationally, HeartBeam said it advanced its strategic focus on heart attack assessment, receiving U.S. Food and Drug Administration Breakthrough Device Designation and acceptance into the agency's Total Product Life Cycle Advisory Program, or TAP. Those designations are significant because they can give a small medical device developer earlier and more frequent interaction with regulators, which may matter as the company moves toward a U.S. pivotal study. HeartBeam plans to finalize the design of that study in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027.
The clinical groundwork is already in place. The company completed enrollment of 486 patients in its HEADSTART-ACS study and reported positive results from its 132-patient ALIGN-ACS pilot study, which demonstrated higher specificity than standard 12-lead electrocardiograms with comparable sensitivity. For patients and clinicians, specificity is central to heart attack assessment: a test that flags too many healthy patients can drive unnecessary emergency care, while one that misses real events can delay treatment. HeartBeam's technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, with the goal of enabling cardiac assessment outside a medical facility. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, and the cleared indications for use are described at https://www.heartbeam.com/indications.
HeartBeam holds more than 20 issued patents related to technology enablement, and the latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. The announcement was distributed through InvestorWire, a communications platform within the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to 5,000+ outlets and social media distribution. Terms of use and disclaimers applicable to the content are available at https://www.InvestorWire.com/Disclaimer.

